Programmatic implications of the TUMIKIA trial on community-wide treatment for soil-transmitted helminths: further health economic analyses needed before a change in policy

Table 1 Hypothetical case study of the estimated financial costs of using different treatment strategies within the Kenyan national STH control programme

Strategy	Number treated	Assumed cost per treatment (US$)	Estimated total financial cost per year (US$)
School-based treatment	6 million children [23]	0.30^b–0.56^c	1.8–3.4 million
Community-wide treatment	14 million individuals^a	0.32^d–0.46^e	4.4–6.4 million

^aApproximated based on demographic data from the World Bank [24]
^bBased on the WHO MDA cost benchmark model [25]
^cEstimate from Evidence Action (a programmatic estimate for 2015) [23]
^dBased on the estimate from the TUMIKIA trial [4]: routine scenario (excluding the research costs) relating to whole county (i.e. estimate at scale). US$0.025 per treatment was added for the cost of albendazole [4]
^eBased on the estimate from the TUMIKIA trial [4]—routine scenario (excluding the research costs) relating to trial areas only. US$0.025 per treatment was added for the cost of albendazole [4]

ISSN: 1756-3305